Home > Dengue
Search results for: Dengue
#32222640 // Save this To Up
Design, expression, and evaluation of novel multiepitope chimeric antigen of Wuchereria bancrofti for the diagnosis of lymphatic filariasis - A structure-based strategy.The Global Program for Elimination Lymphatic Filariasis (GPELF) is in an advanced stage and requires tools for diagnosing infection, assessing transmission and certification. This study was aimed at developing an antibody-based assay using a chiemric antigen containing multi-B-cell epitopes from antigens highly expressed in different stages of Wuchereria bancrofti to detect LF infection and its transmission. The antigen was express cloned and two indirect ELISA based (IgG1 & IgG4 based) antibody assays were developed using the recombinant antigen. The chimeric antigen displayed 1 and 3-fold reactivity with IgG1 and IgG4 antibodies, respectively in microfilaraial (mf) positive sera when compared to that in sera samples of Non-endemic normal sera (NEN) (O.D, 0.13 ± 0.20 and 0.18 ± 0.07), thus differentiating infected from uninfected individuals. In IgG1 and IgG4 antibody assays, the multiepitope antigen also showed reactivity (O.D, 0.27 ± 0.18 and 0.16 ± 0.03) in a small proportion (18 and 30, respectively out of 156) endemic normal individuals and in IgG1 antibody in a few (4) chronic patients (CP). The antigen did not react with IgG1 or IgG4 antibodies in the sera samples of malaria, scrub typhus, dengue, hookworm, and roundworm helminth cases (0.139 ± 0.018, 0.144 ± 0.007 0.17804 ± 0.007 and 0.162 ± 0.006), thus showing its high specificity. The sensitivity (%) and specificity (%) of the multi-epitope antigen-based IgG1 and IgG4 antibody assays are 100, 98.1 and 100, 99.52, respectively. Thus, the recombinant multiepitope antigen appears to have good potential in detecting active LF infection and in assessing its transmission in endemic communities.
1130 related Products with: Design, expression, and evaluation of novel multiepitope chimeric antigen of Wuchereria bancrofti for the diagnosis of lymphatic filariasis - A structure-based strategy.Anti CML Monoclonal Antib Ofloxacin CAS Number [824 MOUSE ANTI BORRELIA BURGD Mouse Anti-Ca19.9 Sialyl MarkerGeneTM Fluorescent rHIV gp36, insoluble Anti Human Rotavirus antigen,R Recombinant HCV NS-4a+b A Mouse PAI-1 (wild type ac Lymphatic tissue tumor te Mouse AntihnRNPQ Target A Androgen Receptor Antibod
#32221545 // Save this To Up
Minority Gene Expression Profiling: Probing the Genetic Signatures of Pathogenesis Using Ribosome Profiling.Minority Gene Expression Profiling (MGEP) refers to a scenario where the expression profiles of specific genes of interest are concentrated in a small cellular pool that is embedded within a larger, non-expressive pool. An example of this is the analysis of disease-related genes within sub-populations of blood or biopsied tissues. These systems are characterized by low signal-to-noise ratios that make it difficult, if not impossible, to uncover the desired signatures of pathogenesis in the absence of lengthy, and often problematic, technical manipulations. We have adapted ribosome profiling (RP) workflows from the Illumina to the Ion Proton platform and used them to analyze signatures of pathogenesis in an MGEP model system consisting of human cells eliciting <3% productive dengue infection. We find that RP is powerful enough to identify relevant responses of differentially expressed genes, even in the presence of significant noise. We discuss how to deal with sources of unwanted variation, and propose ways to further improve this powerful approach to the study of pathogenic signatures within MGEP systems.
1132 related Products with: Minority Gene Expression Profiling: Probing the Genetic Signatures of Pathogenesis Using Ribosome Profiling.G418 sulfate (Geneticin d pCAMBIA1105.1 (GusPlus™ Gene Expression: Mouse N pCAMBIA2301 Vector (gusA Transcription factors: O pCAMBIA0305.2 Vector (Sec pCAMBIA1300 Vector (No Re pCAMBIA1391Z Vector (gusA DNA (cytosine 5) methyltr pCAMBIA1200 Vector (No Re Cancer miRNA Profiling Pl pCAMBIA2300 Vector (No Re
#32220845 // Save this To Up
A non-live preparation of sp. Panama () is a highly effective larval mosquito biopesticide.Given the continued high prevalence of mosquito-transmitted diseases there is a clear need to develop novel disease and vector control strategies. Biopesticides of microbial origin represent a promising source of new approaches to target disease transmitting mosquito populations. Here we describe the development and characterization of a novel mosquito biopesticide, derived from an air-dried, non-live preparation of the bacterium sp. Panama (Family: ). This preparation rapidly and effectively kills the larvae of prominent mosquito vectors, including the dengue and Zika vector , and the human malaria vector During semi-field trials in Puerto Rico, we observed high efficacy of the biopesticide against field-derived populations, and against and larvae in natural breeding water, indicating the suitability of the biopesticide for use under more natural conditions. In addition to high efficacy, the non-live biopesticide has a low effective dose, a long shelf life, high heat stability, and can be incorporated into attractive larval baits, all of which are desirable characteristics for a biopesticide. We have developed a novel preparation to kill mosquitoes from an abundant soil bacterium, sp. Panama. This preparation is an air-dried powder containing no live bacteria, which can be incorporated into an attractive bait and fed directly to mosquito larvae. We demonstrate that the preparation has broad spectrum activity against the larval form of the mosquitoes responsible for the transmission of malaria and the dengue, chikungunya, Yellow Fever, West Nile and Zika viruses, as well as mosquito larvae that are already resistant to commonly used mosquitocidal chemicals. Our preparation possesses many favourable traits: it kills at a low dosage, and does not lose activity when exposed to high temperatures, all of which suggest it could eventually become an effective new tool for controlling mosquitoes and the diseases they spread.
1333 related Products with: A non-live preparation of sp. Panama () is a highly effective larval mosquito biopesticide.Rabbit Anti-MDMX Polyclon Rabbit Anti-RPS3 Polyclon Rabbit Anti-HIRA DGGR1 Po Mouse Anti-BrdU(A7) Monoc Rabbit Anti-CD20 Polyclon Rabbit Anti-phospho-CstF6 Rabbit Anti-SORBS2 ArgBP2 Rabbit Anti-ICAM4 CD242 P Rabbit Anti-intestinal FA anti-Peroxiredoxin Ⅳ, R Rabbit Anti-VTG Polyclona Rabbit Anti-ASB12 Polyclo
#32220286 // Save this To Up
Balanced immunity is key for a successful dengue vaccine.
MOUSE ANTI HUMAN CD15, Pr Dengue Type 1 antibody, M NATIVE HUMAN PROLACTIN, P 10X PHOSPHATE BUFFERED SA MOUSE ANTI HUMAN CD19 RPE Dengue Type 3 antibody, M MOUSE ANTI CANINE DISTEMP MOUSE ANTI BOVINE ROTAVIR MOUSE ANTI APAAP COMPLEX, Dengue antibody (Complex) 10x ELISA WASH BUFFER, Pr NATIVE HUMAN PROLACTIN, P
#32220283 // Save this To Up
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.The Butantan Institute has manufactured a lyophilised tetravalent live-attenuated dengue vaccine Butantan-DV, which is analogous to the US National Institutes of Health (NIH) TV003 admixture. We aimed to assess the safety and immunogenicity of Butantan-DV.
2297 related Products with: Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.Prostate cancer, hyperpla Interferon-γ | Interfer DVL1 & CSNK2A1 Protein Pr ANILLIN Scraps (internal) FDA Standard Frozen Tissu 9-(4’-Aminophenyl)-9H-p anti-Diazepam Binding Inh ABCE1 RNAse L inhibitor A Rabbit Anti-Cell death in FDA Standard Frozen Tissu FDA Standard Frozen Tissu N-(4-Acetamidophenyl)indo
#32218580 // Save this To Up